These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37579734)

  • 1. Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab.
    Angelova-Toshkina D; Weide B; Tietze LF; Hebst M; Tietze JK
    Oncology; 2024; 102(1):76-84. PubMed ID: 37579734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of baseline metabolic tumor volume measured on
    Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
    Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
    Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
    Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
    Bhave P; Ahmed T; Lo SN; Shoushtari A; Zaremba A; Versluis JM; Mangana J; Weichenthal M; Si L; Lesimple T; Robert C; Trojanello C; Wicky A; Heywood R; Tran L; Batty K; Dimitriou F; Stansfeld A; Allayous C; Schwarze JK; Mooradian MJ; Klein O; Mehmi I; Roberts-Thomson R; Maurichi A; Yeoh HL; Khattak A; Zimmer L; Blank CU; Ramelyte E; Kähler KC; Roy S; Ascierto PA; Michielin O; Lorigan PC; Johnson DB; Plummer R; Lebbe C; Neyns B; Sullivan R; Hamid O; Santinami M; McArthur GA; Haydon AM; Long GV; Menzies AM; Carlino MS
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.
    Gambichler T; Brown V; Steuke AK; Schmitz L; Stockfleth E; Susok L
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):972-977. PubMed ID: 29024038
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
    Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
    Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
    Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
    Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
    Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
    Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S
    J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
    Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
    JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
    Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.